The purpose of this study is to learn about how much the study medicine PF-07976016 will be taken up and processed by healthy male participants. The total number of weeks of the study is up to approximately 12 weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
8
\[14C\] PF-07976016 liquid (oral) formulation
PF-07976016 liquid (oral) formulation
\[14C\] PF-07976016 intravenous (IV) formulation
ICON
Groningen, Netherlands
Total recovery of radioactivity expressed as a percent of total oral radioactive dose administered.
Time frame: From dose (Day 1) and for up to 21 days thereafter
Number of participants with treatment emergent adverse events
Time frame: First dose (Day 1) through 28 to 35 days after final dose (approximately 12 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.